Sars-Cov2 (COVID-19) may invade the CNS inducing neurological diseases such as anosmia, ageusia, encephalitis, ischemic or hemorrhagic stroke. Management of severe neurological complications in COVID-19 patients may require ventricular cerebrospinal fluid drainage and cranial decompression. During surgery, cerebrospinal fluid, meninges and brain parenchyma can be safely removed from the patient. In this study, COVID-19 patients will be evaluated first, for the presence of Sars-Cov2 in the cerebrospinal fluid and/or biopsies and second, for the consequences of Sars-Cov2 neuroinfection in terms of inflammatory and immune responses.
Drug: Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies
Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies
Inclusion Criteria:
- COVID-19 patients requiring an external ventricular drain, a decompressive craniectomy
or an intracranial hematoma surgery
Exclusion Criteria:
- Pregnant or lactating women
Fondation A de Rothschild
Paris, France
Pierre BOURDILLON, MD, Principal Investigator
Fondation A. de Rothschild